Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 17/20 | 0.63 |
| ▸ | KDR | P35968 | 10/20 | 0.59 |
| ▸ | SRC | P12931 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22044880 | 0.84 | RET (0.71) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL22044152 | 0.83 | RET (0.59) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL22044022 | 0.83 | RET (0.68) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL22044091 | 0.82 | RET (0.62) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL12436139 | 0.82 | RET (0.69) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL22044148 | 0.81 | RET (0.63) | RETKDRSRCABL1 | |
| SCHEMBL22043994 | 0.80 | RET (0.57) | RETKDR | |
| SCHEMBL20875066 | 0.78 | RET (1.00) | RETKDR | |
| SCHEMBL30071217 | 0.78 | RET (1.00) | RETKDR | |
| SCHEMBL22044087 | 0.78 | RET (0.52) | RETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | RET 597/4885KDR 1054/4885SRC 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.